Louisiana chucks Risperdal settlement

Share this article:

A Louisiana appeals court has overturned a Risperdal settlement to Johnson & Johnson's advantage. Bloomberg reports that the court tossed a $257.7 million deceptive marketing verdict, saying prosecutors failed to provide enough evidence of wrongdoing.

Despite the local win for J&J, Louisiana is just a minor point in a bigger marketing tangle, which includes allegations from the Department of Justice that the drugmaker's marketing strategies triggered fraudulent government payments for the anti-psychotic, and allegations of tying speaker fees to prescription rates, among others.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.